Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
39 hedge funds and large institutions have $11.8M invested in Soleno Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
193% more call options, than puts
Call options by funds: $126K | Put options by funds: $43K
0% more funds holding
Funds holding: 39 → 39 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.05% less ownership
Funds ownership: 2.45% → 2.41% (-0.05%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
56% less capital invested
Capital invested by funds: $27.1M → $11.8M (-$15.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$101K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$47.1K |
| 3 |
Renaissance Technologies
New York
|
+$35.1K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$21.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$242K |
| 2 |
OC
Oppenheimer & Co
New York
|
-$237K |
| 3 |
E
Ergoteles
New York
|
-$69K |
| 4 |
Two Sigma Investments
New York
|
-$39.4K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$28K |
SLNO Hedge Fund Activity: Q4 2021 in Review
39 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2021, worth a combined $11.8M — down 56% from $27.1M a quarter earlier.
Fund positioning in SLNO was balanced in Q4 2021: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 8 trimmed.
The largest buyer was Granite Point Capital Management, adding an estimated $101K. The largest seller was Two Sigma Advisers, cutting an estimated $242K.
- 39 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $11.8M of Soleno Therapeutics stock for Q4 2021, down 56% quarter-over-quarter.
- 5 funds opened new Soleno Therapeutics positions in Q4 2021 and 5 closed out, a net change of 0 holders.
- The largest Soleno Therapeutics buyer in Q4 2021 was Granite Point Capital Management, an estimated $101K added.
- The largest Soleno Therapeutics seller in Q4 2021 was Two Sigma Advisers, an estimated $242K sold.
Based on aggregated 13F filings for Q4 2021.